Ani Pharmaceuticals (ANIP) Goodwill (2013 - 2026)

Ani Pharmaceuticals has disclosed Goodwill across 14 years of filings, most recently posting $62.5 million for Q1 2026.

• Goodwill for Q1 2026 came in at $62.5 million, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.5 million (up 3.0% YoY), and the FY2025 annual result was $62.5 million, up 4.15% from the prior year.
• Goodwill came in at $62.5 million for Q1 2026 at Ani Pharmaceuticals, roughly flat from $62.5 million in the prior quarter.
• In the past five years, Goodwill ranged from a high of $62.5 million in Q3 2025 to a low of $28.2 million in Q1 2022.
• The 5-year median for Goodwill is $28.2 million (2022), against an average of $41.8 million.
• Across the five-year window, Goodwill surged 688.3% in 2022 and changed 0.0% in 2023, its largest moves.
• Ani Pharmaceuticals' Goodwill stood at $28.2 million in 2022, then grew by 0.07% to $28.2 million in 2023, then jumped by 112.57% to $60.0 million in 2024, then grew by 4.15% to $62.5 million in 2025, then changed by 0.0% to $62.5 million in 2026.
• The last three Goodwill figures came in at $62.5 million (Q1 2026), $62.5 million (Q4 2025), and $62.5 million (Q3 2025), per Business Quant data.